THIS WEEK'S FEATURE
Despite being a new entrant in the cannabis market, Zenabis Global (TSX:ZENA) is making huge strides to become one of the largest licensed producers of medical and adult-use recreational cannabis in Canada.
XORTX Therapeutics (CSE:XRX; OTCQB:XRTXF) is awaiting several key milestones during the next few months as it works to redefine how progressive kidney disease is treated.
Oragenics (NYSE American: OGEN) is leveraging its synthetic biology platforms to address two significant unmet medical needs: oral mucositis (OM) and multi drug-resistant (MDR) bacterial infections.
BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) has reported impressive early safety and efficacy data with its lead immunotherapies for the treatment of advanced breast cancer.
MediXall Group (OTCQB:MDXL) has launched a new generation healthcare marketplace platform to address self-pay and high deductible consumers’ growing need for greater healthcare cost transparency and access to competitive pricing information.